United Therapeutics stock
Price history
+22.52% over the period1 year: from $471.92 (November 17, 2025) to $578.20 (November 17, 2026), +22.52%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 17, 2026 | $578.20 |
| October 30, 2026 | $598.72 |
| September 30, 2026 | $541.89 |
| August 31, 2026 | $510.38 |
| July 31, 2026 | $517.71 |
| June 30, 2026 | $541.83 |
| May 29, 2026 | $556.82 |
| April 30, 2026 | $571.35 |
| March 31, 2026 | $592.98 |
| February 27, 2026 | $503.90 |
| January 30, 2026 | $469.49 |
| December 31, 2025 | $487.25 |
| November 28, 2025 | $486.00 |
| November 17, 2025 | $471.92 |
At a glance
The company
Develops and commercializes drugs and organ transplant products for pulmonary arterial hypertension, neuroblastoma, pulmonary fibrosis and related diseases
Latest results
Quarter to September 30, 2026 · EPS $5.71 (estimate $6.21)
TickerLandia's take on United Therapeutics
- Pricier than usual relative to earnings: P/E on the latest fiscal year 21 vs a median of 14 over its last 9 fiscal years.
- Cheaper than similar companies: trailing 12-month P/E 22 vs 28 (−20%) in a group of 9.
- Strong point: Profitability (88/100 in its group). Weak point: Earnings stability (37/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−4.91% from the 52-week high
Analysts · 15 analysts
Average target$687.14+17.64% vs. price
Buy 12 · Hold 2 · Sell 1 · Buy
TickerLandia Fingerprint: United Therapeutics
Compared with similar companies: very high profitability and very high financial strength.
Financials and price compared with 39 companies in the drug manufacturers - specialty & generic industry, worldwide. Momentum and risk compared with 883 North American stocks.
Priceaverage55
How much it costs relative to what it produces.
Metric Value Position in group Forward P/E 17.0 39 EV/EBITDA 17.0 56 Price/book 3.97 57 Price/sales 7.85 82 P/E (trailing 12 months) 22.2 41 Profitabilityvery high88
How much it earns on revenue and capital.
Metric Value Position in group ROA 10.9% 80 Operating margin 39.4% 96 Gross margin 86.3% 91 Net margin 38.6% 96 ROE 19.1% 75 Earnings stabilitylow37
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 7.4% 12 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 63 Growthaverage50
How fast revenue and earnings are growing.
Metric Value Position in group Average revenue growth (3 years) +18.02% 91 Revenue growth (year over year) +4.10% 26 Earnings growth (year over year) −20.30% 35 Financial strengthvery high82
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Net debt/EBITDAcounts in reverse: lower means more financial strength · more cash than debt −0.95 82 Interest coverage 77.8 76 Current ratio 4.61 88 Dividendno dividend
How much it returns to shareholders, and for how long.
Market momentumstrong69
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (3 months) +19.96% 90 Relative strength (6 months) +2.62% 49 1-year return +23.77% 67 Distance from 200-day average +8.45% 69 Riskaverage43
How much the price swings.
Metric Value Position in group Volatility (60 days) 40.2% 63 Beta (1 year) 0.41 37 Maximum drawdown (12 months) 20.9% 29
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 18, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
United Therapeutics is pricier than in the past and cheaper than similar companies
On the latest fiscal year's earnings (2025), United Therapeutics's P/E today is 20.8, above the median of its last 9 fiscal years (14.3; between 8.13 and 21.5 from 2016 to 2025). United Therapeutics's P/E (trailing 12 months): 22.2, −20% against the median of a group of 9 similar companies (27.6).
Compared with 9 similar companies
| Metric | United Therapeutics | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 22.2 | Middle | |
| Forward P/E | 17.0 | Middle | |
| Operating margin | 39.4% | High | |
| ROE | 19.1% | Middle | |
| Price/book | 3.97 | Low |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: United Therapeutics. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
$832.5M
Latest quarter · Q3 2026
Net income
$258.6M
Latest quarter · Q3 2026
Quarterly net margin
31.1%
Latest quarter · Q3 2026
Numbers and valuation
Full valuation- Market cap
- $25.04B
- P/E
- 22.2
- EPS
- $26.49
- Volume
- 424.5K
- Daily trading
- €279.36M
- Dividend yield
- 0.00%
How United Therapeutics is changing
All resultsRevenue grew 16.5% a year on average over the last 5 years
Operating margin fell from 50.6% to 46.9%
Free cash flow equal to 82% of net income
Returns
United Therapeutics returns
$1,000 invested in United Therapeutics 5 years ago, on November 17, 2021, would be worth $2,900 today: +189.95% in total, +23.73% per year. This is the price return only: dividends are excluded.
| Period | United Therapeutics | S&P 500 | $1,000 becomes |
|---|---|---|---|
| 1 month | +6.45% | −3.17% | $1,065 |
| 6 months | +2.73% | +0.11% | $1,027 |
| Year to date | +18.66% | +8.34% | $1,187 |
| 1 year | +22.52% | +11.15% | $1,225 |
| 3 years | +152.55% | +64.30% | $2,526 |
| 5 years | +189.95% | +58.18% | $2,900 |
| 10 years | +333.07% | +239.10% | $4,331 |
Over the last 6 months it has done better than 27% of the stocks in the Healthcare sector.
Price only, without dividends. Calculate your investment
The chart in detail
United Therapeutics: technical analysis
United Therapeutics is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 4.0% below its all-time closing high ($608.49, November 4, 2026).
- Trend
- Upward
- RSI (14 sessions)
- 55
- Between 30 and 70
- vs 200-session average
- +8.45%
Active signals
Golden cross: the 50-session average has crossed above the 200-session average.
since November 9, 2026
Support and resistance
Price areas where United Therapeutics has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance$610.49+4.52%3 touches, last on November 4, 2026
- Last price$584.10
- Support$583.09−0.17%2 touches, last on October 1, 2026
- Support$557.96−4.47%6 touches, last on November 9, 2026
- Support$535.55−8.31%6 touches, last on August 27, 2026
Volatility and risk
Over the last year it has moved less than the S&P 500.
- Beta (1 year) vs S&P 500
- 0.41
- Volatility (60 sessions, annualised)
- 40.2%
- Largest fall in the last year
- −20.87%
Close of November 17, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
United Therapeutics: seasonality
Average monthly price change over 28 years
Over the last 28 years, the strongest month for United Therapeutics has been November: +5.55% on average, positive in 17 years out of 27. The weakest has been April: −2.20% on average, positive in 11 years out of 27.
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +0.53% | −1.42% | 12 of 27 |
| February | +2.19% | +0.23% | 14 of 27 |
| March | +1.35% | −0.61% | 13 of 27 |
| April | −2.20% | −1.68% | 11 of 27 |
| May | +4.70% | +4.11% | 15 of 27 |
| June | +2.69% | +2.30% | 14 of 27 |
| July | +4.09% | +1.46% | 16 of 28 |
| August | +4.96% | −0.57% | 14 of 28 |
| September | +1.74% | −0.74% | 13 of 28 |
| October | +0.08% | +3.10% | 18 of 28 |
| November | +5.55% | +4.28% | 17 of 27 |
| December | +2.99% | +1.66% | 16 of 27 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
United Therapeutics and its competitors
Based in Silver Spring, Maryland, United Therapeutics Corporation has existed since 1996 and develops and commercializes products for patients with chronic and life-threatening diseases. Its treatments for pulmonary arterial hypertension form the core of its range, including the inhaled Tyvaso DPI and Nebulized Tyvaso, the injectable Remodulin, the tablet Orenitram and the oral Adcirca. It also sells Unituxin, a monoclonal antibody for high-risk neuroblastoma, and the Remunity Pump, a pump and controller for Remodulin.
- Headquarters
- Silver Spring, United States
- Employees
- 1,400
- Founded
- 1996
- Chief executive
- Martine Rothblatt
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| United TherapeuticsUTHR | $25.04B | 39.4% | 22.2 | +2.73% |
| ViatrisVTRS | $23.58B | — | — | +24.09% |
| ZoetisZTS | $33.92B | 37.9% | 14.1 | +12.48% |
| Neurocrine BiosciencesNBIX | $16.73B | 26.6% | 24.5 | +4.73% |
| Teva Pharmaceutical IndustriesTEVA | $49.67B | 19.8% | 99.0 | +24.29% |
| Hims & Hers HealthHIMS | $4.13B | -6.4% | — | −29.94% |
Same industry or related industries, similar size. Compare United Therapeutics with its competitors · Full profile
